A dengue vaccination trial conducted by France’s Sanofi Pasteur in fiveAsian countries, including Vietnam, showed the efficacy in 56.5 percentof dengue-infected cases.
The vaccination alsoprevented 67 percent of the sufferers from being hospitalized, heard aconference reviewing the efficacy of the vaccination in the community inHo Chi Minh City on November 3.
The trial wasundertaken on 10,275 children and teenagers aged 2 to 14 in Indonesia,Malaysia, the Philippines, Thailand and Vietnam.
InVietnam, from September 2011, 2,336 children in the two Mekong Deltaprovinces of An Giang and Tien Giang got vaccinated.
At the conference, director of the Health Ministry’s PreventiveMedicine Department Tran Dac Phu noted that a lack of dengue vaccine is ahuge burden on not only Vietnam but many other countries.
The dengue vaccine research programme has been conducted by SanofiPasteur over the past 20 years, with the participation of Ho Chi MinhCity’s Pasteur Institute. It will be implemented until November 2017.
According to the World Health Organisation, each year,an estimated 50 million people contract dengue, of whom 500,000 requirehospitalization and 25,000 die.
Sanofi Pasteur, thevaccines division of Sanofi, provides more than one billion doses ofvaccine each year, making it possible to immunize more than 500 millionpeople across the globe.
A world leader in thevaccine industry, Sanofi Pasteur offers the broadest range of vaccinesprotecting against 20 infectious diseases.-VNA
The vaccination alsoprevented 67 percent of the sufferers from being hospitalized, heard aconference reviewing the efficacy of the vaccination in the community inHo Chi Minh City on November 3.
The trial wasundertaken on 10,275 children and teenagers aged 2 to 14 in Indonesia,Malaysia, the Philippines, Thailand and Vietnam.
InVietnam, from September 2011, 2,336 children in the two Mekong Deltaprovinces of An Giang and Tien Giang got vaccinated.
At the conference, director of the Health Ministry’s PreventiveMedicine Department Tran Dac Phu noted that a lack of dengue vaccine is ahuge burden on not only Vietnam but many other countries.
The dengue vaccine research programme has been conducted by SanofiPasteur over the past 20 years, with the participation of Ho Chi MinhCity’s Pasteur Institute. It will be implemented until November 2017.
According to the World Health Organisation, each year,an estimated 50 million people contract dengue, of whom 500,000 requirehospitalization and 25,000 die.
Sanofi Pasteur, thevaccines division of Sanofi, provides more than one billion doses ofvaccine each year, making it possible to immunize more than 500 millionpeople across the globe.
A world leader in thevaccine industry, Sanofi Pasteur offers the broadest range of vaccinesprotecting against 20 infectious diseases.-VNA
